Sage Therapeutics-JPM-202401.pdf

1、J.P.Morgan Healthcare ConferenceJanuary 2024Sage Therapeutics 2024Safe Harbor Statement The slides presented today and the accompanying oral presentations contain forward-looking statements,which may be identified by the use of words such as“may,”“might,”“will,”“should,”“can,”“expect,”“plan,”“antici

2、pate,”“believe,”“estimate,”“project,”“intend,”“future,”“opportunity”,“goal”,“mission”,“potential,”“target”,or“continue,”and other similar expressions.Forward-looking statements in this presentation include statements regarding:plans,expectations and goals for commercialization of ZURZUVAE as a treat

3、ment for women with PPD,including our goal for ZURZUVAE to become first line therapy and standard of care in this indication and our reimbursement/access goals;our belief in the potential benefit and profile of ZURZUVAE in the treatment of PPD;the potential for success of our commercialization of ZU

4、RZUVAE for women with PPD;the potential for success of our other product candidates in various indications,including the potential profile and benefit of our other product candidates;our clinical development plans,including expected timelines for activities and our expectations as to potential resul

5、ts;our estimates as to the number of patients with disorders and diseases of interest to us and that we hope to help and the potential market for approved products and for our product candidates,if approved;the potential drivers of value in our business;the opportunity,mission,goals and vision for o

6、ur business;and our expectations with respect to maintaining a strong financial foundation.These forward-looking statements are neither promises nor guarantees of future performance,and are subject to a variety of risks and uncertainties,many of which are beyond our control,which could cause actual